AR074915A1 - Derivados de 2-piridin-2-il-pirazol-3(2h)-ona, composiciones farmaceuticas que los comprenden y uso de los mismos para el tratamiento de trastornos del aparato cardiovascular, glaucoma y otras patologias. - Google Patents
Derivados de 2-piridin-2-il-pirazol-3(2h)-ona, composiciones farmaceuticas que los comprenden y uso de los mismos para el tratamiento de trastornos del aparato cardiovascular, glaucoma y otras patologias.Info
- Publication number
- AR074915A1 AR074915A1 ARP090105126A ARP090105126A AR074915A1 AR 074915 A1 AR074915 A1 AR 074915A1 AR P090105126 A ARP090105126 A AR P090105126A AR P090105126 A ARP090105126 A AR P090105126A AR 074915 A1 AR074915 A1 AR 074915A1
- Authority
- AR
- Argentina
- Prior art keywords
- group
- pyrazol
- dihydro
- pyridin
- groups
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6875—Nucleoproteins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/10—Screening for compounds of potential therapeutic value involving cells
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pathology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Obesity (AREA)
- Ophthalmology & Optometry (AREA)
- Neurology (AREA)
- Vascular Medicine (AREA)
- Dermatology (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
Abstract
Reivindicación 1: Compuesto que responde a la fórmula (1) en la que R representa un grupo -SO2NR3R4, un átomo de hidrógeno, un átomo de halógeno, un grupo -halógenoalquilo C1-5, un grupo -CO2R5 o un grupo -SO2-R4; siendo R3, R4, R5 tales como se definen a continuación: R1 representa un grupo heterocicloalquilo que no contiene átomo de nitrógeno, un grupo -W-cicloalquilo C3-6, -W-arilo, -W-heteroarilo, -W-heterocicloalquilo, -W-COOR5 o un grupo -W-CONR5R6, (i) estando dichos grupos arilo, heteroarilo y heterocicloalquilo sustituidos opcionalmente en al menos un átomo de carbono con al menos un sustituyente elegido entre los átomos de halógeno, los grupos alquilo C1-5, -alquileno C1-5-O-alquilo C1-5, -alcoxi C1-5, una función hidroxi, los grupos -halógenoalquilo C1-5, una función ciano, los grupos -O-alquileno C1-5-O-alquilo C1-5, los grupos -O-alquileno C1-5-NR5R6, los grupos -SO2-alquilo C1-5, los grupos -NR5R6 y los grupos -CO2R5 y (ii) entendiéndose que cuando se trata de un grupo heterocicloalquilo, dicho grupo comprende al menos un átomo de nitrógeno, pudiendo éste último contener opcionalmente un sustituyente elegido entre los grupos alquilo C1-5; R2 representa un átomo de hidrógeno, un grupo -alquilo C1-5, -alquileno C1-5-O-alquilo C1-5, un grupo -halógenoalquilo C1-5, un grupo -W-COOR5, -W-C(O)NHR5 o un grupo -W-C(O)-NR5R6; siendo W, R5 y R6 tales como se definen a continuación; entendiéndose que: n representa 0, 1 ó 2; W es (i) un grupo -alquileno C1-5, sustituido opcionalmente con un grupo elegido entre los grupos -(CH2)n-CO2R5 y los grupos -(CH2)n-(CO)NR5R6, con n tal como se ha definido anteriormente y R5 y R6 tales como se definen a continuación; o (ii) un grupo -cicloalquileno C3-6-; o R3 y R4 (i) Idénticos o diferentes, representan, independientemente el uno del otro, un átomo de hidrógeno, un grupo -alquilo C1-5, -cicloalquilo C3-6, -alquileno C1-5-O-alquilo C1-5, un arilo, un grupo -CH2-arilo, un heteroarilo, un heterocicloalquilo, un grupo -W-OH, un grupo -W-CHOH-CH2OH, un grupo -W-CO2R5, -W-NR5R6 o un grupo -W-O-(CH2)n-arilo; estando dichos grupos -cicloalquilo C3-6 y heterocicloalquilo sustituidos opcionalmente, en al menos un átomo de carbono con al menos un grupo elegido entre -alquilo C1-5, -alcoxi C1-5, una función hidroxi, un grupo -W-NR5R6 y un grupo -W-CO2R5, en el caso de los grupos -cicloalquilo C3-6 y heterocicloalquilo y/o en al menos un heteroátomo elegido entre nitrógeno con al menos un grupo elegido entre -alquilo C1-5 en el caso de un grupo heterocicloalquilo, con W y n tales como se han definido anteriormente y R5 y R6 tales como se definen a continuación y entendiéndose que cuando R3 y R4 son idénticos, no pueden ser un átomo de hidrógeno; (ii) o bien R3 y R4 forman junto con el átomo de nitrógeno al que están unidos un grupo heterocicloalquilo, sustituido opcionalmente en al menos un átomo de carbono y/o, llegado el caso, en al menos un heteroátomo, con al menos un sustituyente elegido entre los grupos -alquilo C1-5 y los grupos -CH2-arilo; R5 y R6, idénticos o diferentes, representan, independientemente el uno del otro, un átomo de hidrógeno, un grupo -alquilo C1-5 o un grupo halógenoalquilo C1-5, en el estado de base o de sal de adición a un ácido, con la excepción de los compuestos siguientes: 4-bencil-2-(piridin-2-il)-1,2-dihidro-3H-pirazol-3-ona; 4-(2,4-diclorobencil)-2-(piridin-2-il)-1,2-dihidro-3H-pirazol-3-ona; 4-(4-metoxibencil)-2-(piridin-2-il)-1,2-dihidro-3H-pirazol-3-ona; 4-(4-bromobencil)-2-(piridin-2-il)-1,2-dihidro-3H-pirazol-3-ona; 2-(piridin-2-il)-4-[2-(trifluorometil)bencil]-1,2-dihidro-3H-pirazol-3-ona; 4-(4-clorobencil)-2-(piridin-2-il)-1,2-dihidro-3H-pirazol-3-ona; 4-(1,3-benzodioxol-5-ilmetil)-2-(piridin-2-il)-1,2-dihidro-3H-pirazol-3-ona; 4-(3-metilbencil)-2-(piridin-2-il)-1,2-dihidro-3H-pirazol-3-ona; 4-(2-clorobencil)-2-(piridin-2-il)-1,2-dihidro-3H-pirazol-3-ona; 4-(4-metilbencil)-2-(piridin-2-iI)-1,2-dihidro-3H-pirazol-3-ona; 4-(3-clorobencil)-2-(piridin-2-il)-1,2-dihidro-3H-pirazol-3-ona; 4-(4-terc-butilbencil)-2-(piridin-2-il)-1,2-dihidro-3H-pirazol-3-ona; 4-bencil-5-metil-2-(piridin-2-il)-1,2-dihidro-3H-pirazol-3-ona; 5-metil-4-(1-feniletil)-2-(piridin-2-iI)-1,2-dihidro-3H-pirazol-3-ona; 4-bencil-2-(6-cloropiridin-2-il)-5-metil-1,2-dihidro-3H-pirazol-3-ona; 4-{1-[4-(dietilamino)fenil]etil}-5-metil-2-(piridin-2-il)-1,2-dihidro-3H-pirazol-3-ona.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0807474A FR2940651B1 (fr) | 2008-12-29 | 2008-12-29 | Derives de 2-pyridin-2-yl-pyrazol-3(2h)-one,leur preparation et leur application en therapeutique comme activateurs de hif |
| FR0904092A FR2949466A1 (fr) | 2009-08-28 | 2009-08-28 | Derives de 2-pyridin-2-yl-pyrazol-3(2h)-one, leur preparation et leur application en therapeutique comme activateurs de hif |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR074915A1 true AR074915A1 (es) | 2011-02-23 |
Family
ID=42008610
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP090105126A AR074915A1 (es) | 2008-12-29 | 2009-12-28 | Derivados de 2-piridin-2-il-pirazol-3(2h)-ona, composiciones farmaceuticas que los comprenden y uso de los mismos para el tratamiento de trastornos del aparato cardiovascular, glaucoma y otras patologias. |
Country Status (35)
| Country | Link |
|---|---|
| US (1) | US8541455B2 (es) |
| EP (1) | EP2382205B1 (es) |
| JP (1) | JP5734870B2 (es) |
| KR (1) | KR20110099786A (es) |
| CN (1) | CN102333769B (es) |
| AR (1) | AR074915A1 (es) |
| AU (1) | AU2009334569B2 (es) |
| BR (1) | BRPI0924060A8 (es) |
| CA (1) | CA2748411A1 (es) |
| CL (1) | CL2011001496A1 (es) |
| CO (1) | CO6400141A2 (es) |
| CR (1) | CR20110361A (es) |
| CY (1) | CY1115368T1 (es) |
| DK (1) | DK2382205T3 (es) |
| EA (1) | EA019591B1 (es) |
| EC (1) | ECSP11011155A (es) |
| ES (1) | ES2481042T3 (es) |
| HR (1) | HRP20140680T1 (es) |
| IL (1) | IL213789A (es) |
| MA (1) | MA32976B1 (es) |
| MX (1) | MX2011007054A (es) |
| MY (1) | MY179093A (es) |
| NZ (1) | NZ593751A (es) |
| PA (1) | PA8856201A1 (es) |
| PE (1) | PE20120416A1 (es) |
| PL (1) | PL2382205T3 (es) |
| PT (1) | PT2382205E (es) |
| SG (1) | SG172803A1 (es) |
| SI (1) | SI2382205T1 (es) |
| SM (1) | SMT201400097B (es) |
| TN (1) | TN2011000267A1 (es) |
| TW (1) | TWI482763B (es) |
| UY (1) | UY32369A (es) |
| WO (1) | WO2010076524A2 (es) |
| ZA (1) | ZA201104783B (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY155244A (en) | 2008-12-29 | 2015-09-30 | Sanofi Sa | Derivatives of 2-pyridin-2-yl-pyrazol-3(2h)-one, preparation and therapeutic use thereof |
| JP5902671B2 (ja) * | 2011-03-31 | 2016-04-13 | キッセイ薬品工業株式会社 | ベンジルピラゾール誘導体の製造方法およびその製造中間体 |
| JP6126078B2 (ja) * | 2012-03-30 | 2017-05-10 | 第一三共株式会社 | ４−アルカノイルアミノ−３−ピラゾロン誘導体 |
| ES2660914T3 (es) * | 2013-03-29 | 2018-03-26 | Takeda Pharmaceutical Company Limited | Derivados de 6-(5-hidroxi-1H-pirazol-1-il)nicotinamida y su uso como inhibidores de PHD |
| DE102016223133A1 (de) | 2016-11-23 | 2018-05-24 | Deere & Company | Geschwindigkeitskontrolle einer Erntemaschine |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4023488A1 (de) * | 1990-07-24 | 1992-01-30 | Bayer Ag | 1-(pyri(mi)dyl-(2)) -5-hydroxy-pyrazol-mikrobizide |
| US5750088A (en) | 1993-03-30 | 1998-05-12 | The Dupont Merck Pharmaceutical Company | Stable hydrazones linked to a peptide moiety as reagents for the preparation of radiopharmaceuticals |
| JP4499721B2 (ja) | 2003-06-30 | 2010-07-07 | ヒフ バイオ，インク． | 化合物、組成物および方法 |
| DE102005019712A1 (de) * | 2005-04-28 | 2006-11-09 | Bayer Healthcare Ag | Dipyridyl-dihydropyrazolone und ihre Verwendung |
| PE20071020A1 (es) | 2006-03-07 | 2007-12-11 | Smithkline Beecham Corp | Compuestos derivados de glicina n-sustituidos como inhibidores de prolil hidroxilasa |
| WO2008047198A1 (en) | 2006-10-16 | 2008-04-24 | Pfizer Products Inc. | Therapeutic pyrazolyl thienopyridines |
| DE102006050516A1 (de) | 2006-10-26 | 2008-04-30 | Bayer Healthcare Ag | Substituierte Dihydropyrazolone und ihre Verwendung |
| RU2009146851A (ru) | 2007-05-18 | 2011-06-27 | Байер Шеринг Фарма Акциенгезельшафт (DE) | Гетероарил-замещенные пиразольные производные, которые могут использоваться для лечения гиперпролиферативных нарушений и заболеваний, связанных с ангиогенезом |
-
2009
- 2009-12-24 EP EP09805789.6A patent/EP2382205B1/fr active Active
- 2009-12-24 JP JP2011542886A patent/JP5734870B2/ja not_active Expired - Fee Related
- 2009-12-24 WO PCT/FR2009/052691 patent/WO2010076524A2/fr active Application Filing
- 2009-12-24 PE PE2011001292A patent/PE20120416A1/es not_active Application Discontinuation
- 2009-12-24 MY MYPI2011003012A patent/MY179093A/en unknown
- 2009-12-24 SI SI200930983T patent/SI2382205T1/sl unknown
- 2009-12-24 MX MX2011007054A patent/MX2011007054A/es active IP Right Grant
- 2009-12-24 MA MA34027A patent/MA32976B1/fr unknown
- 2009-12-24 CA CA2748411A patent/CA2748411A1/fr not_active Abandoned
- 2009-12-24 AU AU2009334569A patent/AU2009334569B2/en not_active Ceased
- 2009-12-24 KR KR1020117017676A patent/KR20110099786A/ko not_active Application Discontinuation
- 2009-12-24 PL PL09805789T patent/PL2382205T3/pl unknown
- 2009-12-24 SG SG2011047503A patent/SG172803A1/en unknown
- 2009-12-24 ES ES09805789.6T patent/ES2481042T3/es active Active
- 2009-12-24 PT PT98057896T patent/PT2382205E/pt unknown
- 2009-12-24 NZ NZ593751A patent/NZ593751A/xx not_active IP Right Cessation
- 2009-12-24 DK DK09805789.6T patent/DK2382205T3/da active
- 2009-12-24 CN CN200980157590.6A patent/CN102333769B/zh not_active Expired - Fee Related
- 2009-12-24 EA EA201170899A patent/EA019591B1/ru not_active IP Right Cessation
- 2009-12-24 BR BRPI0924060A patent/BRPI0924060A8/pt not_active IP Right Cessation
- 2009-12-28 AR ARP090105126A patent/AR074915A1/es unknown
- 2009-12-28 TW TW098145336A patent/TWI482763B/zh not_active IP Right Cessation
- 2009-12-29 UY UY0001032369A patent/UY32369A/es not_active Application Discontinuation
- 2009-12-29 PA PA20098856201A patent/PA8856201A1/es unknown
-
2011
- 2011-05-24 TN TN2011000267A patent/TN2011000267A1/fr unknown
- 2011-06-17 CL CL2011001496A patent/CL2011001496A1/es unknown
- 2011-06-22 EC EC2011011155A patent/ECSP11011155A/es unknown
- 2011-06-23 CR CR20110361A patent/CR20110361A/es unknown
- 2011-06-27 IL IL213789A patent/IL213789A/en not_active IP Right Cessation
- 2011-06-28 ZA ZA2011/04783A patent/ZA201104783B/en unknown
- 2011-06-29 US US13/172,305 patent/US8541455B2/en not_active Expired - Fee Related
- 2011-06-29 CO CO11081326A patent/CO6400141A2/es active IP Right Grant
-
2014
- 2014-07-15 HR HRP20140680AT patent/HRP20140680T1/hr unknown
- 2014-07-22 SM SM201400097T patent/SMT201400097B/xx unknown
- 2014-07-23 CY CY20141100553T patent/CY1115368T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR084588A1 (es) | Compuesto heterociclico fusionado y su uso para el control de plagas | |
| RU2386622C2 (ru) | Гетероароматические производные мочевины и их применение в качестве активаторов глюкокиназы | |
| PE20080895A1 (es) | Dihidropirazolonas sustituidas como inhibidores de hif-propil-4-hidroxilasas | |
| AR108388A2 (es) | Compuestos de oxazol sustituidos con indazol como inhibidores de pi3-quinasas | |
| CL2012001171A1 (es) | Procedimiento para la preparacion del ester n-[[2-[[[4-[[[(hexiloxicarbonil)]4-amino]iminometil]fenil]amino]metil]1-alquil-1h-benzimidazol-5-il]carbonil]n-2-piridinil-etilico de beta-alanina; y uno de los compuestos intermediarios considerados. | |
| AR072166A1 (es) | Derivado de piperidina y su uso como inhibidor de renina superior | |
| AR087196A1 (es) | Metodos plaguicidas que utilizan compuestos de 3-piridil tiazol sustituido y derivados para combatir las plagas de animales ii | |
| AR057704A1 (es) | Inhibidores macrociclicos del virus de la hepatitis c, composicion farmaceutica y proceso de preparacion del compuesto | |
| AR076415A1 (es) | Compuestos heterociclicos nitrogenados fusionados y su uso en el control de artropodos | |
| PE20142099A1 (es) | Derivados de sulfonamida | |
| AR074435A1 (es) | Derivados de 1,3-benzotiazol, medicamentos que los contienen y uso de los mismos en el tratamiento del cancer. | |
| AR056536A1 (es) | Compuestos de 2-amino-5- [4-(difluormetoxi)fenil]-5-fenilimidazolona como inhibidores de la beta secretasa (bace) | |
| AR061603A1 (es) | Derivados de etenilcarboxamidas microbicidas | |
| PE20070189A1 (es) | COMPUESTO DE AMINO-5-HETEROARILO (5 MIEMBROS) IMIDAZOLONA Y SU USO PARA MODULACION DE LA ß-SECRETASA | |
| PE20080906A1 (es) | Derivados heteroarilo como inhibidores de citocina | |
| AR074915A1 (es) | Derivados de 2-piridin-2-il-pirazol-3(2h)-ona, composiciones farmaceuticas que los comprenden y uso de los mismos para el tratamiento de trastornos del aparato cardiovascular, glaucoma y otras patologias. | |
| PE20121159A1 (es) | DERIVADOS DE PIRIDINA, PIRAZINA Y QUINOLINA COMO INHIBIDORES DE LA FOSFOINOSITIDA 3 CINASA Y LA mTOR | |
| AR052330A1 (es) | Derivados de adamantano que comprenden quinoleinas sustituidas | |
| AR083953A1 (es) | Compuestos para tratar enfermedades neurodegenerativas | |
| PE20141191A1 (es) | Compuestos como inhibidores de bace | |
| PE20081378A1 (es) | Derivados de 1,2,4-triazol como moduladores de mglur5 | |
| AR044874A1 (es) | Derivados de 4- cianopirazol-3 - carboxamida, su preparacion y su aplicacion en terapeutica | |
| PE20080843A1 (es) | Inhibidores de renina y metodo para su utilizacion | |
| AR073932A1 (es) | Compuestos de esteres de acido 2-(aminometiliden)-4,4-difluoro-3- oxobutirico y procedimiento para su preparacion | |
| PE20140703A1 (es) | Derivados de heteroarilo como moduladores de nachr alfa 7 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |